150 related articles for article (PubMed ID: 10537305)
1. Successful immunotherapy of an intraocular tumor in mice.
Schurmans LR; den Boer AT; Diehl L; van der Voort EI; Kast WM; Melief CJ; Toes RE; Jager MJ
Cancer Res; 1999 Oct; 59(20):5250-4. PubMed ID: 10537305
[TBL] [Abstract][Full Text] [Related]
2. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
3. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
4. Macrophages are vital in spontaneous intraocular tumor eradication.
Boonman ZF; Schurmans LR; van Rooijen N; Melief CJ; Toes RE; Jager MJ
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2959-65. PubMed ID: 16799039
[TBL] [Abstract][Full Text] [Related]
5. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
Chen PW; Uno T; Ksander BR
Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
[TBL] [Abstract][Full Text] [Related]
6. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.
Dace DS; Chen PW; Alizadeh H; Niederkorn JY
J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163
[TBL] [Abstract][Full Text] [Related]
7. Complete elimination ('cure') of progressively growing intraocular tumors by local injection of tumor-specific CD8+ T lymphocytes.
Miki S; Ksander B; Streilein JW
Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3622-34. PubMed ID: 8258521
[TBL] [Abstract][Full Text] [Related]
8. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.
Toes RE; Offringa R; Blom RJ; Brandt RM; van der Eb AJ; Melief CJ; Kast WM
J Immunol; 1995 Apr; 154(7):3396-405. PubMed ID: 7534797
[TBL] [Abstract][Full Text] [Related]
9. Adoptive transfer of immunity to intraocular tumors in mice.
Niederkorn JY; Streilein JW
Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):336-42. PubMed ID: 6421767
[TBL] [Abstract][Full Text] [Related]
10. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.
Dace DS; Chen PW; Niederkorn JY
J Immunol; 2007 May; 178(10):6115-22. PubMed ID: 17475837
[TBL] [Abstract][Full Text] [Related]
11. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
[TBL] [Abstract][Full Text] [Related]
12. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.
Toes RE; Blom RJ; van der Voort E; Offringa R; Melief CJ; Kast WM
Cancer Res; 1996 Aug; 56(16):3782-7. PubMed ID: 8706024
[TBL] [Abstract][Full Text] [Related]
13. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
14. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
15. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
[TBL] [Abstract][Full Text] [Related]
16. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites.
Ksander BR; Streilein JW
J Immunol; 1990 Oct; 145(7):2057-63. PubMed ID: 1975822
[TBL] [Abstract][Full Text] [Related]
17. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
Boonman ZF; van Mierlo GJ; Fransen MF; Franken KL; Offringa R; Melief CJ; Jager MJ; Toes RE
J Immunol; 2004 Feb; 172(3):1567-74. PubMed ID: 14734736
[TBL] [Abstract][Full Text] [Related]
18. Gammadelta T cells in anterior chamber-induced tolerance in CD8(+) CTL responses.
Xu Y; Kapp JA
Invest Ophthalmol Vis Sci; 2002 Nov; 43(11):3473-9. PubMed ID: 12407158
[TBL] [Abstract][Full Text] [Related]
19. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
Ksander BR; Bando Y; Acevedo J; Streilein JW
Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
[TBL] [Abstract][Full Text] [Related]
20. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
Wenkel H; Chen PW; Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
